Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

839 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiomic Features Applied to Contrast Enhancement Spectral Mammography: Possibility to Predict Breast Cancer Molecular Subtypes in a Non-Invasive Manner.
Nicosia L, Bozzini AC, Ballerini D, Palma S, Pesapane F, Raimondi S, Gaeta A, Bellerba F, Origgi D, De Marco P, Castiglione Minischetti G, Sangalli C, Meneghetti L, Curigliano G, Cassano E. Nicosia L, et al. Among authors: curigliano g. Int J Mol Sci. 2022 Dec 5;23(23):15322. doi: 10.3390/ijms232315322. Int J Mol Sci. 2022. PMID: 36499648 Free PMC article.
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls.
Morganti S, Ivanova M, Ferraro E, Ascione L, Vivanet G, Bonizzi G, Curigliano G, Fusco N, Criscitiello C. Morganti S, et al. Among authors: curigliano g. Cancer Drug Resist. 2022 Oct 20;5(4):971-980. doi: 10.20517/cdr.2022.55. eCollection 2022. Cancer Drug Resist. 2022. PMID: 36627895 Free PMC article.
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, Pierce KJ, Mutka SC, Wainberg ZA. Curigliano G, et al. Br J Cancer. 2023 Jan;128(2):400. doi: 10.1038/s41416-023-02161-w. Br J Cancer. 2023. PMID: 36697966 Free PMC article. No abstract available.
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
Bosi C, Bartha Á, Galbardi B, Notini G, Naldini MM, Licata L, Viale G, Mariani M, Pistilli B, Ali HR, André F, Piras M, Callari M, Barreca M, Locatelli A, Viganò L, Criscitiello C, Pusztai L, Curigliano G, Győrffy B, Dugo M, Bianchini G. Bosi C, et al. Among authors: curigliano g. Eur J Cancer. 2023 Dec;195:113379. doi: 10.1016/j.ejca.2023.113379. Epub 2023 Oct 11. Eur J Cancer. 2023. PMID: 37913680 Free article.
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, Johnson BE, Meyerson M, Jeselsohn R, Qiu X, Li R, Long H, Winer EP, Dillon D, Curigliano G, Cherniack AD, Tolaney SM, Lin NU. Tarantino P, et al. Among authors: curigliano g. Nat Commun. 2023 Nov 18;14(1):7496. doi: 10.1038/s41467-023-43324-w. Nat Commun. 2023. PMID: 37980405 Free PMC article.
839 results